ArticleBMC urology2026
Urinary adhesion molecules with ERK signaling as predictive biomarkers for kidney stones: a pilot study.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundNoninvasive diagnostic biomarkers should be researched to reduce the need for imaging and radiation exposure in patients with kidney stone disease. This pilot study aimed to evaluate the diagnostic potential of urinary p-ERK/t-ERK (inflammatory signaling), osteopontin, CD44, and annexin II (adhesion molecule) levels in predicting kidney stone disease.
methodsThirty-seven participants were enrolled: 20 with and 17 without the disease. Spot urine samples were collected for crystal count and biochemical analyses. Enzyme-linked immunosorbent assay was performed to measure p-ERK/t-ERK in urine sediment and urinary osteopontin, CD44, and annexin II levels. Pearson's correlation and receiver operating characteristic curve analyses were used to assess the correlations and diagnostic values of these biomarkers.
resultsThe stone group showed significantly higher levels of p-ERK1/2 activity and urinary adhesion proteins (osteopontin, CD44, and annexin II) compared with those in the non-stone group. Receiver operating characteristic curve analysis revealed that these biomarkers could moderately distinguish between stone and non-stone groups. A multivariable logistic model combining CD44², ERK/CD44, and CD44/annexin II demonstrated enhanced discriminatory potential, achieving an AUC-ROC of 0.88. Additionally, annexin II levels showed a weak positive correlation with stone number and could distinguish patients with three or more stones from those with fewer.
conclusionsThis is the first study to reveal the concurrent elevation of ERK-related inflammatory signaling and urinary adhesion molecules in association with kidney stone disease. These markers could serve as potential candidate biomarkers for non-invasive diagnosis and disease monitoring. Our findings offer preliminary insights into the pathophysiology of kidney stones and may aid in future diagnostic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.